Dysmenorrhea in Combination with Endometriosis in Adolescence and Early Reproductive Age

О.Л. Иванишкина-Кудина
In: Репродуктивное здоровье. Восточная Европа · 2022 · pp. 288–294 · doi:10.34883/pi.2022.12.2.012 · W4281732458
OA: bronze CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper reports the high prevalence of dysmenorrhea in young women and adolescents, advocating for timely diagnosis and progesterone therapy to optimize treatment efficiency and minimize side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Распространенность дисменореи среди женщин молодого возраста и подростков крайне высока. Своевременная диагностика первичной и вторичной форм дисменореи в молодом возрасте позволяет выбрать обоснованную патогенетическую терапию прогестероном, которая даст возможность совместить высокую эффективность с одновременным снижением нежелательных медикаментозных и гормональных нагрузок при длительной терапии заболевания. The prevalence of dysmenorrhea among young women and adolescents is extremely high. Diagnosis of primary and secondary forms of dysmenorrhea at a young age makes it possible to choose a reasonable pathogenetic progesterone therapy, which will combine high efficiency and at the same time reduce unwanted drug and hormonal during long-term therapy of the disease.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (12)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK